The Indian Council of Medical Research (ICMR) said India’s Covid-19 vaccine, Covaxin, has attracted global attention.
In a tweet, the ICMR said: “India’s indigenous vaccine against # Covid19 Covaxin, a product of the ICMR-Bharat Biotech collaboration, achieves an extraordinary feat. The data generated by India underscore Covaxin’s impressive safety and immunogenicity profile and spur Lancet interest in publishing them. “
The ICMR said: “The encouraging results of the COVAXIN Phase I and II trials have paved the way for the Phase III clinical trial in India, which is currently ongoing at 22 sites.”
The New Delhi-based All India Institute of Medical Sciences (AIIMS) on Thursday invited volunteers for the phase III clinical trial of the indigenously developed Covid-19 vaccine candidate “Covaxin” of which it is one of the sites.
“AIIMS, New Delhi is a site for the COVAXIN Phase III clinical trial. This is an inactivated whole virion vaccine co-sponsored by the Indian Council of Medical Research (ICMR) and Bharat Biotech, ”AIIMS said in an advertisement.
AIIMS Center for Community Medicine, Dr. Sanjay K Rai has informed through advertising that Phase I / II (safety and immunogenicity) studies have already been completed.